← Eichor
Study identifier: NCT07290270 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Condition: Metastatic Prostate Cancer  ·  Sponsor: Novartis Pharmaceuticals

PhaseN/A
Planned participants170
Who can joinMale, 18 Years to 99 Years
Healthy volunteersNo

About this study

This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals  ·  +41613241111  ·  novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (1)

Novartis Investigative SiteShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07290270